CRISPR Therapeutics AG (CRSP) Institutional Ownership

Ownership Summary

CRISPR Therapeutics AG (NASDAQ:CRSP) has 483 institutional investors that have filed 13F reports for the period ending March 2026.

• Collectively, these holders controlled 80.3% of CRISPR Therapeutics AG's outstanding shares in March 2026, down from 87.7% in December 2025.
• Their total shares held in CRSP increased 2.75% quarter over quarter, and separately, investors owning CRISPR Therapeutics AG increased 22.28% from a year ago.
• Of these 483 holders, 255 added to their stakes in CRISPR Therapeutics AG, 112 trimmed positions, and 116 made no changes.
• The aggregate institutional position in CRISPR Therapeutics AG amounted to 77.08Mn shares as of March 2026, up by 2.06Mn shares quarter on quarter, and up 10.85Mn shares year over year.
• As of March 31, 2026, ARK Investment Management LLC held the largest stake in CRISPR Therapeutics AG with 11.31Mn shares, accounting for 11.78% of total shares outstanding.
• The most significant purchases of CRSP for the quarter ending March 2026 came from Capital World Investors (4.73Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.14Mn), TWO SIGMA INVESTMENTS, LP (1.01Mn), ARK Investment Management LLC (791.57K), VANGUARD PORTFOLIO MANAGEMENT LLC (546.83K).
• The biggest sellers of CRISPR Therapeutics AG for the quarter ending March 2026 included Capital International Investors (4.71Mn), T. Rowe Price Investment Management, Inc. (2.12Mn), UBS Group AG (761.61K), Squarepoint Ops LLC (427.53K), DIMENSIONAL FUND ADVISORS LP (412.89K).
• Per Business Quant, the top 10 investors in CRSP for the quarter ending March 2026 include ARK Investment Management LLC (11.31Mn), BlackRock, Inc. (7.68Mn), Orbis Allan Gray Ltd (6.11Mn), Capital World Investors (4.73Mn), State Street Corp (3.98Mn), GSK plc (3.22Mn), T. Rowe Price Investment Management, Inc. (2.95Mn), GEODE CAPITAL MANAGEMENT, LLC (2.38Mn), SR ONE CAPITAL MANAGEMENT, LP (2.04Mn), FMR LLC (1.95Mn).